The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
What’re people’s thoughts on the capacity figures?
My thoughts: 5 mil a month initial capacity from GAD. It sounds like TT from GAD to BBI and Abingdon is well underway, so add another potential 5? Million a month once that’s complete? So 10 million a month from already disclosed manufacturing partners, when all firing on all cylinders. My guess is that then the final up to 20 million a month would come from additional GAD capacity (potentially currently reserved for ‘sovereign’ test) and ODX?
Just my musings.
Detects the SA variant, in discussions with PHE, up to 30m capacity a month in the UK alone, wordwide demand, CE mark VERY early in May, first commercial batches already produced by GAD. Yet....... down we go :-) you couldn’t make it up really. Every single presentation, the same sh@t from the market.
@Rollyroll
You don’t care about the company, you just care about your investment? If you can’t see that the two go hand in hand, then you should really be asking your Mum and Dad to put your pocket money to better use. Utter clown.
I’m not sure even Rolly knows what he’s doing here. Morning drinker perhaps? Might explain his outbursts.
Rollyroll is an utter cretin and should have been banned for life, after his abhorrent personal attack on AS a couple of weeks ago. Ironically Rollyroll just autocorrected to Rolly troll on my phone :-)
Fair enough, Wolves. It was a genuine question, one investor to another. I just wasn’t sure on why you would be alarmed, when we’ve already pretty much been told (albeit in an interview) that we shouldn’t expect anything until next Tuesday at the earliest.
Why would you be alarmed, Wolves? Al said a few weeks in the latest interview (hence the sell off, in my opinion). Next Tuesday will be 3 weeks since the interview was recorded. So why would you be alarmed? You could argue that 3 weeks is the minimum that ‘a few’ would mean.
My opinion FWIW is that we’re probably looking at next week (still around end Q1, for the scared among us). Al said a few weeks in his interview 2 weeks ago, and I’ll go with that. Also, it could well drop back to £1.90 ish before then, but guess what? That’s where we rose to after the last actual news from the company, so you could argue that’s fine for now. As a LTH, why would you care anyway? You clearly believe it’s coming, and when it does, the sky is the limit. Just my opinion.
@Rollyroll
‘No words needed’ ‘thanks a lot Avacta’
Are you actually a 12 year old girl? Jesus Christ, grow up. Why are you even having a hissy fit? No deadline has been missed. You couldn’t make it up.
For what it’s worth, I think Awax comment was very tongue in cheek and almost certainly meant as a joke. They may very well correct me on this point, but peoples sense of humour is quite hard to judge when not face to face.
@DonaldTrumpsWig
I think that any so called ‘mate’ who laughed at me when I lost a significant amount of money (on paper) in one day, would no longer be a mate of mine :-)
Our next key milestone is full clinical validation and CE marking of our lateral flow antigen test which we anticipate will be around the end of this quarter and I look forward to updating the market when that milestone is achieved."
For me, ‘around the end of this quarter’ could be any day now. Anybody disagree that we’re already around the end of the quarter? Circa 10 weeks down, and just over 3 left. Just my opinion. Around the end of the quarter doesn’t have to mean a few days either side of 31st March.
Cheers, Zoom. That’s along the lines of what I was thinking / hoping. Fingers crossed that it’s well underway. I can’t see why you wouldn’t go straight into validation after initial results. What would be the point in waiting?
This is probably what I mean (taken from the TU)
the Group will now progress to a full clinical validation with a larger number of patient samples to CE mark the test for professional use
So does ‘progress to‘ mean progress to starting it? Or progress to the rubber stamp because it’s already started?
I have a quick question, if somebody with some knowledge would be kind enough to help out.
When Avacta state something along the lines of ‘moving towards full clinical validation with a larger number of patient samples’ do people take that to mean that CV has started and moving towards means an actual result of the validation? Or do we think it means that they are preparing to start? I can’t quite work it out.
@DonaldTrumpsWig, I was thinking exactly the same this morning. The November update RNS inferred that clinical evaluation would immediately begin. We now know that there were issues getting the test into Europe, but I also believe that the UK evaluation would have been completed long ago. Although, wouldn’t they have had to release these data?
Haha, DOH. It could be us, couldn’t it? Might it be? FINALLY, is this us?
@Wyndrum, why would we expect a ‘delays encountered’ update at this point? Tech Transfer to BBI started circa 3 months ago, and typically takes 3-4 months (as stated on their own website). We also had the investor presentation a few weeks ago in which we were given plenty of info on the reasons for the delay in BAMS validation.
Oh, and that mortgage will post some rubbish, rambling joke involving Yorkshire tea.
Not sure Zoom. What we can say with 100% certainty though is that on multiple occasions people will post links to other random tests asking, is this ours? / could this be us? even though we haven’t competed tech transfer yet. Dead Cert.